First-in-Class Oral Semaglutide Article Swipe

View

Related Concepts

Semaglutide Medicine Context (archaeology) Type 2 Diabetes Mellitus Glucagon-like peptide-1 Intensive care medicine Type 2 diabetes Diabetes mellitus Endocrinology Paleontology Biology Liraglutide

Sujoy Ghosh , Rajesh Rajput , Samar Banerjee , Beena Bansal , Manoj Chawla , AbhayI Ahluwalia , Tejal Lathia , AshokK Das ·

YOU? · · 2022 · Open Access · · DOI: https://doi.org/10.4103/ijem.ijem_217_22 · OA: W4312656237

Despite the availability of multiple therapeutic options and strategies, patients with type 2 diabetes mellitus (T2DM) the world over have inadequate glycaemic control and India is no exception. Patients with T2DM in India have benefitted from glucagon-like peptide-1 analogues similar to that of patients from other parts of the world. However, subcutaneous treatment with glucagon-like peptide-1 receptor agonists (GLP-1 RAs) is limited by their injectable mode of administration. The present review highlights barriers to incretinisation with GLP-1RAs and the role of first-in-class oral semaglutide in the Indian context and provides guidance to physicians on its initiation and uses.